نتایج جستجو برای: peptide receptor radionuclide therapy
تعداد نتایج: 1363778 فیلتر نتایج به سال:
Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide such as Lu-177 label with a pharmaceutical agent useful to destroy the lesion. The amount of Lu-177 radioactivity administered to the patients is still not standardize and generally not more than 7.4 GBq per session due to the patient’s safety issues. The first cycle of Lu-177 is a...
Key Messages Octreotide can be used as an adjunctive therapy to increase phosphorus levels in patients with tumor-induced osteomalacia. Malignant phosphaturic mesenchymal tumor (PMT) may benefit from treatment with peptide receptor radionucleotide therapy. Context The success of treatment modalities for malignant PMT is limited. Octreotide has been used to treat hypophosphatemia in patients w...
Malignant insulinoma is a rare neuroendocrine tumor, located exclusively in the pancreas, characterized by severe hypoglycemia secondary to excessive insulin secretion. Somatostatin analogs (SSA) and everolimus have been added classic treatment with diazoxide last years. Peptide receptor radionuclide therapy (PRRT) has also recently tested few patients apparently satisfactory results. We presen...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید